Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy - Frontiers
Peptide Research News surfaces this story from Frontiers. Read the complete article at the original source:
Read the full article at Frontiers →